Patients will get Orkambi by next month after years of price wrangling with manufacturer
Up to 5,000 children and young people in England with the life-shortening disease cystic fibrosis will soon get access to the new drug Orkambi, after the US manufacturer ended years of bitter wrangling and agreed a price with the NHS.
Campaigners celebrated the news, which NHS England’s chief executive said meant cystic fibrosis patients would get the drug within the month. “Given the time it has taken for the company to reach this agreement, there must be no further delay,” wrote Sir Simon Stevens to the chair of the House of Commons health select committee, Sarah Wollaston. The committee held hearings on the impasse earlier this year.
This post was syndicated from Health | The Guardian. Click here to read the full text on the original website.